SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — John Henry Holliday

PatientJohn Henry Holliday
Date of birth2004-08-14
IdentifiersMRN HR-NI007-SYN; SSN (made up) 000-07-8153
Document date2026-08-18
AuthorMartin Beaumont, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

End-of-treatment review after six months. [S]

History of Present Illness

Mr. Holliday returns five days after his last dose. He completed all 182 doses by video-observed therapy: 56 in the intensive phase and 126 in the continuation phase, with the one dose held during the stomach illness in the spring added at the end. The cultures from the third week and from the two-month visit both grew nothing, so the continuation phase stayed at four months. He has had no cough, fever, night sweats, or weight loss for months, and he has gained 7.5 kg. The repeat liver tests planned two weeks after the sick visit, and the monthly tests in the fourth and fifth months, were not drawn; he reported no hepatitis symptoms on any video call. Since the party in the spring he has had a drink or two at most once a week and no heavy drinking. He sees his counselor once a month. [S]

ElementDetail
TreatmentAll 182 doses completed by video-observed therapy
CulturesThird-week and two-month cultures negative
Weight65.5 kg, up 7.5 kg since diagnosis
AlcoholAUDIT-C 3; no heavy drinking since the spring

Review of Systems

SystemResultFinding
RespiratoryNegativeNo cough, sputum, hemoptysis, or breathlessness
ConstitutionalNegativeNo fever, night sweats, or weight loss
GastrointestinalNegativeNo nausea, abdominal pain, or jaundice
NeurologicalNegativeNo numbness or tingling
PsychiatricNegativeMood good; PHQ-9 3; no thoughts of suicide or self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for six monthsOral route2026-02-12 to 2026-08-13completedS
Rifampin 300 mg capsules, two capsules (600 mg) daily600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six monthsOral route2026-02-12 to 2026-08-13completedS
Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phaseOral route2026-02-12 to 2026-04-08completedS
Ethambutol 400 mg tablets, three tablets (1200 mg) daily1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results returnOral route2026-02-12 to 2026-03-10stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route2026-02-12 to 2026-08-13completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-18Body height178cmS
2026-08-18Body weight65.5kgS
2026-08-18Body mass index (BMI) [Ratio]20.7kg/m2S
2026-08-18Systolic blood pressure118mm[Hg]S
2026-08-18Diastolic blood pressure74mm[Hg]S
2026-08-18Heart rate72/minS
2026-08-18Respiratory rate14/minS
2026-08-18Body temperature36.6CelS
2026-08-18Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-18Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-56 U/LNormalS
2026-08-18Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L10-40 U/LNormalS
2026-08-18Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-08-18Hemoglobin [Mass/volume] in Blood14.4g/dL13.2-16.6 g/dLNormalS
2026-08-18Total score [AUDIT-C]3{score}S
2026-08-18Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 2026-08-18; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 65.5 kg, BMI 20.7
EyesNo icterus
RespiratoryClear, with no crackles
AbdomenLiver not enlarged
NeurologicalNormal sensation in the feet

Problems

ProblemClinical statusVerificationCodeProvenance
Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic.
Alcohol use disorder, mild, with binge drinkingactiveconfirmed F10.10S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic.
Acute viral gastroenteritis during tuberculosis treatment, with a mild aminotransferase rise below the threshold for drug-induced liver injury; resolvedresolvedconfirmed A08.4S — Synthetic intercurrent illness chosen to teach the assessment of nausea on isoniazid and rifampin; it does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptom review: cough, sputum, hemoptysis, fever, night sweatsAt least monthly during treatmentCompleted todayNo symptoms
ExaminationWeightAt least monthly during treatmentCompleted today65.5 kg
Medication safetyHepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine)Every visit and every observed doseCompleted todayNone reported at any observed dose
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline, at two weeks, then monthly because of alcohol useCompleted todayALT 30, AST 28 U/L, bilirubin 0.6 mg/dL, all normal at the end of treatment
LaboratoryLiver tests after the sick visit and in months four and fiveTwo weeks after the sick visit, then monthlyDeferredNot drawn: no visit was scheduled between the sick visit and the end of treatment, and no standing order was placed. He reported no hepatitis symptoms on daily video calls, and the end-of-treatment tests are normal, so no harm is evident. Corrective action: standing monthly liver-test orders at the start of treatment for every patient with a risk factor
LaboratoryHemoglobinAt the end of treatment when low at baselineCompleted today14.4 g/dL, up from 12.6 at diagnosis
LaboratorySputum AFB smear and cultureMonthly until two consecutive cultures are negativeCompleted todayTwo consecutive negative cultures (third week and two months); no further sputum needed
LaboratoryTwo-month sputum cultureAt the end of the intensive phase; decides the continuation length in cavitary diseaseCompleted todayNo growth; continuation phase kept at four months
ImagingChest X-rayAt diagnosis; at two months only if the first cultures were negative; at the end of treatment as a new baselineCompleted todayCavity closed; residual right upper lobe scarring
Medication safetyDoses observed and missed (video-observed therapy)Every visitCompleted todayAll 182 doses observed
Medication safetyPeripheral neuropathy check, with pyridoxineEvery visitCompleted todayNo neuropathy; pyridoxine stopped with isoniazid
ReferralNotification of treatment completion to the health departmentAt the end of treatmentCompleted todaySent today
SurveyAlcohol use (AUDIT-C for the past month)Every visitCompleted todayAUDIT-C 3 for the past month
Self-managementBrief counseling about alcohol and liver riskEvery visitCompleted todayLow-risk limits agreed now that treatment is over
ReferralCounseling with a substance-use counselorEvery one to two weeks during treatmentCompleted todayMonthly
SurveyDepression screen (PHQ-9)At diagnosis and at the end of treatmentCompleted todayPHQ-9 3, item 9 scored 0
SurveySuicide-risk review and safety plan, with the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide
ReferralInfectious diseases reviewAt two months and at the end of treatmentCompleted todayDr. Navarro reviewed the end-of-treatment results by message; no routine follow-up

Goal progress:

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Adult preventive visit in about a month. Same-day visit for symptoms of relapse. Next scheduled visit 2026-09-22: adult preventive visit. [S]